ClinicalTrials.gg
RecruitingNCT07296341Updated Jan 14, 2026

HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

A Phase 1/2 interventional study of HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine and HRS-4642;nab-paclitaxel; gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer With, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing KRAS G12D Inhibitor HRS-4642 in Pancreatic Neoplasms — 13 open to participants now, 13 under way, 2 of them phase 3. KRAS G12D Inhibitor HRS-4642 · Pancreatic Neoplasms.

Planned enrollment
7th of 13
60 · median 60
Started
2026
with 5 others
Phase 1/2
3 of 13
3 open now
Primary completion
2027-10
later than 7 of 12 live
Registered
8th of 13
by date
Lead sponsor
3 of 13
Shanghai Hengrui Pharmaceutical Co., Ltd.

Among the 13 studies testing KRAS G12D Inhibitor HRS-4642 in Pancreatic Neoplasms, this one is the 7th largest by planned enrollment, is one of 6 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 7 of the 12 other live ones, and was the 8th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

13 of the 13 studies testing KRAS G12D Inhibitor HRS-4642 in Pancreatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About KRAS G12D Inhibitor HRS-4642

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing KRAS G12D Inhibitor HRS-4642 in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid Tumors

03

Conditions studied

  • Locally Advanced or Metastatic Pancreatic Cancer With
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range of 18-75 years old (inclusive of both ends), gender not limited when signing the form
  2. performance status 0 or 1
  3. of greater than or equal to 12 weeks.
  4. Subjects with unresectable local advanced or pancreatic cancer, and pancreatic duct adenocarcinoma confirmed by histopathology
  5. Provide tumor tissue blocks fixed in formalin, embedded in paraffin, or unstained tumor specimen sections, which can be archived or freshly obtained within 3 years prior to the first study treatment (fresh acquisition is preferred).
  6. At least one is present according to the efficacy evaluation criteria for pancreatic cancer ( 1.1)

Exclusion criteria

Exclusion Criteria:

  1. Accompanied by untreated or active central nervous system (CNS) tumor
  2. Failure to recover toxicity and/or complications from previous interventions to ≤ Level 1 or the levels specified by inclusion and exclusion criteria
  3. Subjects known or suspected to have interstitial pneumonia
  4. According to the common adverse reaction event evaluation criteria NCI-CTCAE v5.0, patients with ≥ grade 3 serous fluid accumulation or imaging evidence of a large amount of abdominal fluid accumulation (those who require therapeutic puncture and drainage within 2 weeks before starting the study treatment, only those with imaging showing a small amount of ascites and no clinical symptoms can be enrolled)
  5. Acute or chronic pancreatitis with significant clinical significance
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    HRS-4642 combination with Adebrelimab Injection, nab-paclitaxel in combination with gemcitabine

    Drug: HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine

  • Active comparator
    nab-paclitaxel in combination with gemcitabine

    Drug: HRS-4642;nab-paclitaxel; gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    PFS is defined as the time from the date of first dose of study drug to the date of the first documentation of disease progression or date of death, whichever occurs first.

    Time frame: From the date of first dose of study drug until progressive disease (PD), death, whichever occurs first, assessed up to 16 months

Secondary outcomes

  1. Objective response rate (ORR)

    Objective response is defined as a best confirmed response of CR or PR by RECIST v1.1 as assessed by the investigator.

    Time frame: up to 10 months following the date the last patient was randomized

  2. disease control rate (DCR)

    Disease Control Rate (DCR) is defined as the frequency and percentage of participants with stable disease (SD) or CR or PR.

    Time frame: up to 10 months following the date the last patient was randomized

  3. Duration of response (DoR)

    Duration of Response (DOR) was defined as the duration between the date of first documented Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) and the date of first documented radiographic progression or death due to any cause as assessed by investigator according to RECIST v1.1.

    Time frame: up to 10 months following the date the last patient was randomized

  4. Overall survival (OS)

    Overall Survival (OS) is defined as the time from the date of first dose to the date of death due to any cause.

    Time frame: From study start until target OS events have occurred (approximately 20 months after last patient enrollment)

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100730, China
    Recruiting
    • Yupei Zhao · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.

Of 115 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 88. This study's planned 21 months is below that.

Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartActual
Jan 8, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07296341
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Jan 8, 2026
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 14, 2026

Study contacts

Zengquan Gu
Contact
zengquan.gu@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: KRAS G12D Inhibitor HRS-4642 · Adebrelimab · Albumin-Bound Paclitaxel · Gemcitabine

Start the discussion